Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment
Bakrania A, Zheng G, Bhat M Pharmaceutics DOI: 10.3390/pharmaceutics14010041 Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2–9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range ofContinue Reading